{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:48:35Z","timestamp":1794577715446,"version":"4.9.1"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.2535","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T11:47:56Z","timestamp":1556884076000},"page":"e192535","source":"Crossref","is-referenced-by-count":1349,"title":["Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs"],"prefix":"10.1001","volume":"2","author":[{"given":"Alyson","family":"Haslam","sequence":"first","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland"},{"name":"Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland"},{"name":"Center for Health Care Ethics, Oregon Health & Science University, Portland"},{"name":"Division of General Medicine, Department of Medicine, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"issue":"1","key":"zoi190110r1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/jamaoncol.2015.0137","article-title":"Immune checkpoint inhibitors.","volume":"1","author":"West","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi190110r2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","article-title":"Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer.","volume":"4","author":"Dine","year":"2017","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"12","key":"zoi190110r5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd4476","article-title":"The immune checkpoint inhibitors: where are we now?","volume":"13","author":"Webster","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"zoi190110r6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"zoi190110r7","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment.","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"zoi190110r8","doi-asserted-by":"publisher","first-page":"e171029","DOI":"10.1001\/jamaoncol.2017.1029","article-title":"Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis.","volume":"3","author":"Blumenthal","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"zoi190110r9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1470-2045(18)30317-6","article-title":"Immunotherapy: hype and hope [editorial].","volume":"19","author":"The Lancet Oncology","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi190110r10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S1470-2045(17)30521-1","article-title":"Calling time on the immunotherapy gold rush [editorial].","volume":"18","author":"The Lancet Oncology","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi190110r11","doi-asserted-by":"publisher","first-page":"e180798","DOI":"10.1001\/jamaoncol.2018.0798","article-title":"Speed of adoption of immune checkpoint inhibitors of programmed cell death 1 protein and comparison of patient ages in clinical practice vs pivotal clinical trials.","volume":"4","author":"O\u2019Connor","year":"2018","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi190110r12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology.","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi190110r15","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1016\/S1556-0864(18)30404-0","article-title":"130O Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): the global, multicentre EXPRESS study.","volume":"13","author":"Dietel","year":"2018","journal-title":"J Thorac Oncol"},{"key":"zoi190110r16","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw378.14","article-title":"Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001,-010, and-024.","volume":"27","author":"Aggarwal","year":"2016","journal-title":"Ann Oncol"},{"issue":"11","key":"zoi190110r17","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"zoi190110r20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ctrv.2018.02.002","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): approaches on special subgroups and unresolved burning questions.","volume":"64","author":"Remon","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"zoi190110r21","article-title":"Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following US regulatory approval","author":"Khozin","journal-title":"Oncologist"},{"issue":"8","key":"zoi190110r22","doi-asserted-by":"publisher","first-page":"e0202725","DOI":"10.1371\/journal.pone.0202725","article-title":"Effectiveness and safety of immune checkpoint inhibitors: a retrospective study in Taiwan.","volume":"13","author":"Hsu","year":"2018","journal-title":"PLoS One"},{"issue":"8S","key":"zoi190110r23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1200\/JCO.2017.35.8_suppl.6","article-title":"Off-label immunotherapy prescription: financial implications for payers and patients.","volume":"35","author":"De Souza","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi190110r24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/j.seminoncol.2018.08.001","article-title":"Desperation oncology.","volume":"45","author":"Fojo","year":"2018","journal-title":"Semin Oncol"},{"key":"zoi190110r3","year":"2018"},{"key":"zoi190110r25","author":"Kolata"},{"key":"zoi190110r4","unstructured":"Rodriguez FernandezC. Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought? https:\/\/labiotech.eu\/features\/pd-1-pd-l1-checkpoint-inhibitors\/. Published September 4, 2018. Accessed October 12, 2018."},{"key":"zoi190110r13","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA approved drug products. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed June 20, 2018."},{"key":"zoi190110r14","unstructured":"American Cancer Society. Understanding your diagnosis: cancer staging. https:\/\/www.cancer.org\/treatment\/understanding-your-diagnosis\/staging.html. Accessed June 27, 2018."},{"key":"zoi190110r18","unstructured":"Healio Immuno-Oncology Resource Center. Phase 3 trial of pembrolizumab for advanced HCC fails to meet primary endpoints. https:\/\/www.healio.com\/hematology-oncology\/gastrointestinal-cancer\/news\/online\/%7Ba1a112d0-3f4c-425b-bb25-0823c56e56e6%7D\/phase-3-trial-of-pembrolizumab-for-advanced-hcc-fails-to-meet-primary-endpoints. Accessed February 27, 2019."},{"key":"zoi190110r19","unstructured":"US Government Accountability Office. New drug approval: FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints. https:\/\/www.gao.gov\/products\/GAO-09-866. Accessed February 27, 2009."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/2\/5\/e192535\/17552975\/haslam_2019_oi_190110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T11:48:03Z","timestamp":1556884083000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2019.2535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]}}}